Alnylam's Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial

Alnylam Pharmaceuticals outlined its development strategy for zilebesiran, an investigational RNAi therapy targeting uncontrolled hypertension in patients with elevated cardiovascular risk. The treatment is designed to provide sustained blood-pressure control with twice-yearly dosing, though no clinical efficacy, safety, regulatory, or financial data were disclosed.